TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: ALPHA Sitagliptin Add on to Metformin (0431-103)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patient Is Currently On Monotherapy With Metformin For At Least 10 Weeks Prior To Study Entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Sitagliptin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Vinorelbine as Induction Chemotherapy Followed Concomitant Chemoradiotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* histologically or cytologically confirmed stage IIIA (only N2),~* dry IIIB previously untreated inoperable NSCLC,~* 18 to 75 years old,~* Karnofsky Performance Status (KPS) ≥ 80%,~* weight loss ≤ 10% within the previous 3 months,~* normal organ functions were eligible.~* at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST version 1.0) \[10\].~Exclusion Criteria:~* stages I, II, IIIA (excepted N2), IIIB with pleural effucion and stage IV,~* pregnant or breastfeeding women. Women of Childbearing Age: Women of childbearing potential should take reliable contraceptive measures~* Symptomatic Neuropathy \> grade 1,~* associated Pathology and/or not controled diseases(cardiac insuficiency, myocardial infarction within 3 months before the inclusion ; hypertension, arythmia or uncontroled hypercalcémia; infection requiering iv antibiotic administration within 2 weeks before inculion),~* other associated cancer with the exception of cervical carcinoma in situ or skin cancer baso-cellular correctely treated,~* Previous treatment with an other antineoplasic,~* Known hypersensibility to drugs with a similar chemical structure ti this studied.~* important malabsorbtion syndrom or disease of gastro-intestinal track,~* Participation to another clinical trial within 30 days before inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vinorelbine cisplatin radiotherapy (Type: EXPERIMENTAL): Induction period + radio chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Estradiol+Drospirenone Versus Estradiol+MPA on Endothelial Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy female postmenopausal volunteers, as defined by absence of menses for at least 12 months and follicle stimulating hormone (FSH) 30 IU/L;~2. Age 45 to 75 years;~3. Systolic blood pressure \<140 and \>90 mmHg and diastolic blood pressure \<90 and \>60 mmHg at the screening visit;~4. No personal history of diabetes;~5. Body mass index \< 30 kg/m2;~6. No clinically significant abnormalities on screening tests (complete blood count, serum electrolytes, liver enzymes, thyroid stimulating hormone, urinalysis, and electrocardiogram).~Exclusion Criteria:~1. Current smoking, defined as smoking within the 12 months before the screening visit;~2. Alcohol intake \>1 beverage per night or history of alcohol abuse;~3. Current or past recreational drug use;~4. Personal history of hypertension, cardiovascular disease (coronary artery disease, congestive heart failure, valvular heart disease, stroke, transient ischemic attack, or intermittent claudication), hyperlipidemia, diabetes (defined as a fasting glucose ≥126 mg/dL), kidney disease, liver disease, venous or arterial thromboembolic disease, adrenal insufficiency, depression, or illness requiring overnight hospitalization in the past 6 months;~5. Risk factors for arterial or venous thromboembolism;~6. Personal history of breast cancer or any other type of cancer;~7. Personal history of endometrial hyperplasia, endometrial cancer, or unexplained vaginal bleeding;~8. History of cervical cancer or abnormal pap smear~9. Prescription or herbal medication use, excluding thyroid hormone supplementation;~10. Ischemic changes on resting electrocardiogram;~11. Serum creatinine ≥ 1.3 mg/dL.~12. Serum potassium level \> 5.0 mmol/L;~13. Known hypersensitivity to any of the study drugs;~14. Other active medical problems detected by examination or laboratory testing, except for treated hypothyroidism.~15. Pregnancy

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Estradiol+MPA (Type: ACTIVE_COMPARATOR): None
- Estradiol+DRSP (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 65 years of age or older~* must anticipate taking warfarin for at least 4 weeks for VTE prophylaxis after hip or knee arthroplasty~* must be able to give written, informed consent~* must have venous access~* must not be institutionalized, incarcerated at the time of enrollment (nursing home okay)~* must have life expectancy \> 6 months~* must have plans to have regular INR monitoring~* willing/able to follow-up in 3-7 weeks with a Doppler Ultrasound~Exclusion Criteria:~* Baseline INR \> 1.35~* knowledge of CYP2C9, VKORC1, or CYP4F2 genotype~* knowledge of warfarin dose requirements from prior warfarin therapy~* absolute contraindication or allergy to warfarin therapy (e.g. pregnancy)~* receiving or planning to receive any anticoagulant besides warfarin (if low molecular weight heparin (LMWH) or subcutaneous heparin is deemed necessary by the clinician after enrollment, such patients will be allowed to remain in the study)~* unlikely to be compliant (e.g. due to history of non-compliance, or alcoholism)~* known thrombophilia, bleeding disorder, or history of serious bleed in the past 2 years (unless caused by trauma)~* personal history of venous thromboembolism

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Target INR 1.8 and Pharmacogenetic (Type: EXPERIMENTAL): The target International Normalized Ratio (INR) is 1.8. Warfarin initiation is via Pharmacogenetic dosing.
- Target INR 2.5 and Pharmacogenetic (Type: EXPERIMENTAL): The target INR is 2.5. Warfarin initiation is via Pharmacogenetic dosing.
- Target INR 1.8 and Clinical (Type: EXPERIMENTAL): The target INR is 1.8. Warfarin initiation is via clinical dosing.
- Target INR 2.5 and Clinical (Type: NO_INTERVENTION): The target INR is 2.5. Warfarin initiation is via clinical dosing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Patient must have at least one inpatient, one physician office visit, or one emergency room visit with a diagnosis of AF on the index date or during the pre-index period.~* Patients must be continuously enrolled in a health plan during the pre-index period~* Patient must have a prescription for dabigatran or warfarin~* Patient must be treatment naive from all oral anticoagulant (OAC) use prior to first OAC prescription~* Aged 18-89 years on the index date. The index date is defined as the date of the first OAC prescription~Exclusion criteria:~* Diagnosis of hyperthyroidism during the pre-index period,~* Having claims for any of the following within 3 months prior to the first diagnosis of AF: cardiac surgery, pericarditis, myocarditis, pulmonary embolism.~* Any patients with at least one medical claim for valvular heart disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- dabigatran (Type: None): None
- warfarin (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with OSA still complaining EDS,refusing nCPAP~* ESS score ≥ 12~Exclusion Criteria:~* Patients suffering from insomnia without OSA~* Co-existing narcolepsy~* Patient with sleep debt not due to OSA~* Acute or chronic severe disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BF2.649 (Type: EXPERIMENTAL): BF2.649 capsules dosed at 5 mg, 10 mg, 20 mg
- Placebo (Type: PLACEBO_COMPARATOR): Capsules of placebo containing lactose with low, medium and high dosage

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic Chronic heart failure (NYHA II, III or IV)~* Left ventricular systolic dysfunction (LVEF ≤ 35%)~* Sinus rhythm and resting heart rate ≥ 70 bpm~* Optimal and unchanged CHF medications or dosages~Exclusion Criteria:~* Unstable condition within previous 4 weeks~* Myocardial infarction or coronary revascularisation within previous 2 months~* Stroke or transient cerebral ischaemia within previous 4 weeks~* Congenital heart disease~* Severe valvular disease~* Active myocarditis~* Permanent atrial fibrillation or flutter

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ivabradine (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Investigation of Effectiveness and Safety of Varenicline Tartrate in Helping People Quit Smoking

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Current cigarette smokers between the ages of 18 and 75 years, who are motivated to stop smoking~Exclusion Criteria:~* Patients currently suffering from depression, or have been diagnosed with depression in the last 12 months, or subjects with past or present history of psychosis, panic disorder, or bipolar disorder~* Any subject with known severe chronic obstructive pulmonary disease (COPD)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Glucocorticosteroid treatment for 12 months at least~* Bone age \< 15 years for a boy and \< 13 years for a girl~* Child measured height \< - 2 SD, Child currently treated by GH~Exclusion Criteria:~* Known diabetes (type 1 or type 2)~* A previous history of intolerance or hypersensitivity to the study drug or to drugs with similar chemical structures

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Somatropin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subject aged \>=18 and \<26 years at the time of enrollment.~2. Healthy subject as determined by medical history, physical examination, and judgment of the investigator.~3. Negative urine pregnancy test for all female subjects.~Exclusion Criteria:~1. Previous vaccination with any meningococcal serogroup B vaccine.~2. Subjects who are scheduled to receive 1 or more doses of an HPV vaccine as part of a 3-dose series during the period between Visit 1 and 28 days after the second vaccination.~3. Subjects receiving any allergen immunotherapy with a nonlicensed product or receiving allergen immunotherapy with a licensed product and are not on stable maintenance doses.~4. A known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as subjects with congenital or acquired defects in B cell function, those receiving chronic systemic (oral, intravenous, or intramuscular) corticosteroid therapy, or those receiving immunosuppressive therapy. Subjects in the United States with terminal complement deficiency are excluded from participation in this study.~5. Significant neurological disorder or history of seizure (excluding simple febrile seizure).~6. Current chronic use of systemic antibiotics.~7. Received any investigational vaccines, drugs, or devices within 28 days before administration of the first study vaccination.~8. Any neuroinflammatory or autoimmune condition, including, but not limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- rLP2086 (Type: EXPERIMENTAL): None
- Control (Type: PLACEBO_COMPARATOR): Steril normal saline solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Chemoprevention Approaches for School-based Malaria Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Students (enrolled in the primary intervention)~* Currently enrolled in the study school~* Plan to attend the study school for the remainder of the school year~* Parent/guardian available to provide written informed consent Household members (enrolled in the Household Prevalence survey)~* Slept in the household for most nights in the last month~* Age 6 months or older~* For minors, parent/guardian available to provide written informed consent~Exclusion Criteria:~Students (enrolled in the primary intervention)~* Current evidence of severe malaria or danger signs~* Known adverse reaction to the study drugs~* History of cardiac problems or fainting~* Taking medications known to prolong QT~* Family history of prolonged QT~* Girls 10 years old and older with epilepsy or psoriasis Household members (enrolled in the Household Prevalence survey)~* Household with more than one school-age child enrolled in the study~* Current evidence of severe malaria or danger signs

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intermittent Screening and Treatment (IST) (Type: EXPERIMENTAL): Students will be screened for infection using a higher sensitivity malaria rapid diagnostic test and treated if positive. Treatment will be with DP (females less than 10 years old and all males) or chloroquine (females 10 years old or older).
- Intermittent Preventive Treatment (IPT) (Type: EXPERIMENTAL): All students are treated at each intervention. Treatment will be with DP (females less than 10 years old and all males) or chloroquine (females 10 years old or older).
- Control (Type: NO_INTERVENTION): Students will not receive preventive treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Atorvastatin on Blood Pressure and Urinary Albumin Excretion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* LDL-C\>130 or \>160 mg/dL (depending on the total risk according to the most recent recommendations25).~* no previous hypolipidemic medication~* ability to provide Informed Consent.~Exclusion Criteria:~* pregnancy or lactation~* myocardial infarction or unstable angina within the past 6 months~* heart failure NYHA class III-IV~* renal disease (SCr\>3 mg/dL or proteinuria\>3g/d)~* liver disease~* history of malignancy~* history of drug or alcohol abuse~* treatment with corticosteroids~* any other condition with poor prognosis~* inability to provide Informed Consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RCT of Effects of Device-guided Breathing on Ambulatory BP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Hypertension~* Treated with at least one antihypertensive drug~* BP still not controlled (\>135/85 on Ambulatory BP waking average)~Exclusion Criteria:~* Diabetes~* Atrial Fibrillation~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Resperate device used for 8 weeks (Type: EXPERIMENTAL): Participants to use Resperate device to guide breathing for 8 weeks. After the primary 8-week trial, this group is divided into two subgroups to examine 16-week data: one subgroup that stops using the device after 8 weeks, and one asked to continue to use the device for the full 16 weeks.
- Relaxation control device (Type: ACTIVE_COMPARATOR): Participants use modified device to pace breathing in the 13/minute range for daily practice for 8 weeks and no device thereafter
- Usual Care (Type: NO_INTERVENTION): Participants continue their usual medication and other management for their hypertension. All participants (including UC) are given a home BP monitor and asked to take their BP in morning and evening 3 days/week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* histologically or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma~* Metastatic disease or locally advanced, unresectable disease~* Disease progression during or within 4 months after the last dose of the first-line therapy (platinum/fluoropyrimidine doublet with or without anthracycline)~* Organs are functioning well (liver, kidney, blood)~* Good performance status Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 to 1~Exclusion Criteria:~* First line chemotherapy for metastatic gastric cancer other than platinum/fluoropyrimidine doublet with or without anthracycline~* Previous systemic therapy with other anti-angiogenic drugs~* Uncontrolled high blood pressure~* Symptomatic or poorly controlled heart disease or had a heart attack or stroke within the last 6 month~* Evidence of central nervous system (CNS) metastasis at baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel (Type: EXPERIMENTAL): Ramucirumab (IMC-1211B) DP and Paclitaxel
- Placebo and Paclitaxel (Type: PLACEBO_COMPARATOR): Placebo and Paclitaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete